At the spring 2007 ACS national meeting, Merck Research Laboratories revealed the structure of MK-0974, later known as telcagepant, an experimental treatment for migraine (C&EN, May 7, 2007, page 56). And in 2009, the company unveiled MK-3207, for the same indication (C&EN, April 27, 2009, page 31). Both molecules block the receptor for calcitonin gene-related peptide (CGRP), a neuropeptide implicated in migraine. Both were proven efficacious at treating migraines in patients. And both failed to reach the market. In September 2009, Merck announced it was abandoning MK-3207 because some study subjects had liver test abnormalities, generally after stopping treatment.
by Carmen Drahl |
April 16, 2012